It's hard to improve on that answer, but some of the reforms we're looking at do, in fact, borrow from best practices abroad. Canadians try to incorporate these reforms into our regime and adapt them to the Canadian system. At the end of the day, everybody is struggling with this issue; everybody's grappling with it.
I've heard good things said about the U.K. system, which is one model we're relying on quite heavily in moving forward with these reforms. Anecdotally speaking, I was there last year meeting with a friend of mine who is responsible for rare diseases access for a particular company I won't name, headquartered out of the U.K. I told her it sounded like the U.K. really had it all figured out. Her answer was that the U.K. was the worst country she'd ever worked in. She said her counterparts in other countries would tell her that industry thinks the U.K. is the worst country but that it is somehow getting the best price. We're figuring it out as we go along, but I think we're on the right track.